October 25, 2018 - "The patent outcome enables us to intensify our business development and M&A efforts of broadening our late-stage and commercial product portfolio"
DECEMBER 13, 2018 – Orexo will get back the rights for Zubsolv ex US from its partner Mundipharma. The Company will now initiate formal negotiations with several interested parties enabling to create the best prerequisites for Zubsolv to reach its full potential globally.
DECEMBER 5, 2018 – On December 6, the Capital Markets Day, #OrexoCMD18, will be hosted in Stockholm, Armémuseet, Riddargatan 13, Sweden. For them who will not attend it will be possible to watch it live through below link. A recorded version will be available shortly afterwards.
OCTOBER 25, 2018 - In Q3 2018 Orexo delivered yet another strong quarter in terms of net revenue and profitability, when excluding IP litigation costs. The development was primarily driven by a robust contribution from the US commercial operations, where Zubsolv continued its strong performance versus the same quarter in 2017.
“Addiction is a disease, and it deserves to be treated.” Chris Christie, Former Governor of New Jersey and former C… https://t.co/TbQzEpyQl7
“This crisis started in doctor’s offices in America… it began by using opioids legally and prescribed by physicians… https://t.co/j9Rn42AJyj